SMARCA2 and breast carcinoma: Recent study reported that deletion of KMT2C or KMT2D in non-metastatic breast cancer TNBC models drives BrM through altered H3K4me1, H3K27ac, and H3K27me3 marks, with increased KDM6A binding and MMP3 upregulation [80].